Our press releases
-
Milestone Pharmaceuticals Announces First Patient Randomized in the Phase 3 NODE-301 Clinical Trial Evaluating Etripamil for Termination of Paroxysmal Supraventricular Tachycardia (PSVT) Episodes
-
uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress
-
Sanifit announces completion of enrollment in CaLIPSO – its Phase 2b Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialsis
-
Forbion Portfolio Company Replimune Successfully Completes IPO on NASDAQ
-
enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President
-
Forbion exceeds target with EUR 270 million first close of its fourth life sciences VC fund
-
Hookipa Appoints Dr. Christoph Lengauer as a Non-Executive Director
-
uniQure Inc. - uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B
-
Bio-Techne To Acquire Exosome Diagnostics, Inc.
-
Cellnovo announces the commercialisation of insulin cartridges following the successful start of large-scale manufacturing at the Flex facility in Althofen, Austria
-
Dirk Kersten joins Forbion as General Partner
-
uniQure Announces New Appointments to its Board of Directors
-
Replimune Appoints Dr. Hyam I. Levitsky To Board Of Directors
-
Curetis Launches Unyvero System and LRT Cartridge for Lower Respiratory Tract Infections in the U.S.
-
KaNDy Therapeutics announces positive clinical data with lead candidate NT-814 for the treatment of symptoms of the menopause
-
Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B
-
uniQure Announces the Issuance of New Patents Providing Broad Protection of the Padua Variant of Factor IX in Gene Therapy
-
uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies
-
Curetis Publishes Business and Financial Update for the First Quarter 2018
-
uniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene Therapy
-
uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares
-
uniQure Announces Pricing of its Public Offering (2018)
-
Curetis Announces Change of the Composition of Its Supervisory Board
-
Curetis Publishes Full-Year 2017 Financial Results and Updated Guidance For 2018
-
Curetis to Publish its 2017 Annual Results on April 30, 2018
-
Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018
-
Curetis: Novel Products and Study Data to be Presented at ECCMID 2018
-
Allecra Therapeutics to Present Data at 28th European Congress of Clinical Microbiology and Infectious Diseases
-
Forbion participates in £29M Series B Financing of Enterprise Therapeutics to Advance its Ion Channel Modulators for the treatment of Cystic-fibrosis, COPD and severe asthma
-
Curetis Establishes U.S. Scientific Advisory Board
-
Curetis Receives U.S. FDA De Novo Clearance of Unyvero System and Unyvero LRT Lower Respiratory Tract Infection Cartridge
-
Curetis’ Unyvero BCU Blood Culture Application Receives Approval from Singapore Health Sciences Authority
-
Allecra Therapeutics Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
-
Allecra Therapeutics Announces Positive Top-Line Results from Phase 2 CACTUS Study of its Lead Candidate, AAI101, in Combination with Cefepime to Treat Complicated Urinary Tract Infections (cUTI)
-
Curetis To Attend Key Investor and Scientific Conferences In The Second Quarter 2018
-
Forbion’s Portfolio Company, Prexton Therapeutics Acquired by Lundbeck for up to EUR 905 million (USD 1.1 billion)
-
Curetis Receives USPTO Notice of Allowance for Key Patent Covering Unyvero Technology
-
Forbion leads $19 Million Series B Financing of Escalier Biosciences to Advance its Topical and Systemic RORγt Therapies for Psoriasis and other Autoimmune Diseases
-
AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury
-
Curetis subsidiary Ares Genetics wins incubator stay in Silicon Valley
-
Sanifit Announces Results of the Phase II Clinical Trial of SNF472 in Patients with Calciphylaxis
-
Allecra Therapeutics Announces Fast Track Designation for Lead Antibiotic in Resistant Infections
-
Curetis Group: Ares Genetics Receives Funding Commitment For EUR 1.6 Mio. Project; Curetis Announces Non-Audited Financial Results for 2017
-
Curetis Unyvero HPN Application Receives Singapore Health Sciences Authority Approval; Updates on Sepsis Host Response Test
-
Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology
-
Curetis Expects Near-Term FDA Decision on De Novo Request
-
Sanifit announces the appointment of Cris Calsada as Chief Financial Officer
-
Sanifit Announces Last Patient Last Visit completed in Clinical Trial of SNF472 in Patients with Calciphylaxis
-
uniQure Announces Publication in the Journal Blood of Clinical Data from Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
-
Forbion leads €25 million Series A fundraising in NorthSea Therapeutics and its promising NASH drug programme
